PTD unknown

ptd, page-2

  1. 5,382 Posts.
    G'day Meerkat
    This from Egoli

    Peptech US patent win significant
    May 15, 2002
    Although the market reaction was mixed, analysts believe that 3 more patent applications filed by Peptech Limited (PTD) may eventually provide it with significant additional licence fee revenues. The company currently receives revenue from patents secured in Australia, Europe and the UK but only over 1 in the US.




    Last night Peptech as informed by patent attorneys that “Notices of Allowance” for 3 divisional applications over TNF antibody patents have been issued by the US Patent and Trademarks Office.

    “This brings the number of Notices of Allowance received from the USPTO in respect of Peptech's TNF antibody patent family to four,” commented managing director Stephen Kwik.

    SHAW Stockbroking’s biotechnology analyst David Cooper explained that the notice is a reliable indicator that the company will receive the patent it applied for.

    “Following the issue of a Notice of Allowance, Peptech now has to pay a nominal fee before the patent is printed and then officially issued, with this process usually taking only a few months,” David said.

    Peptech stated that the Notices will help it secure royalty income for sales of products in the US by Centocor, a division of Johnson & Johnson.

    “We are currently receiving ongoing royalties from Centocor for sales of Remicade in Europe, Australia and Canada,” said Mr Kwik.

    “We [believe we] can start receiving royalties from Centocor for Remicade sales in the US when all the patents are issued, and as D2E7 is expected to commence sales in 2003, I continue to be optimistic about the Company's future cash flows” he concluded.

    At 1146 AEST, Peptech Limited shares were trading 14c higher at $3.14, down slightly from its initial surge to $3.27 following the release of the stock to trade.

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.